Sunshine Biopharma (SBFM) Competitors $1.50 -0.01 (-0.86%) As of 10:54 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SBFM vs. ENLV, SCYX, DYAI, COEP, TPST, NRSN, CVKD, CGTX, ALXO, and CARAShould you be buying Sunshine Biopharma stock or one of its competitors? The main competitors of Sunshine Biopharma include Enlivex Therapeutics (ENLV), SCYNEXIS (SCYX), Dyadic International (DYAI), Coeptis Therapeutics (COEP), Tempest Therapeutics (TPST), NeuroSense Therapeutics (NRSN), Cadrenal Therapeutics (CVKD), Cognition Therapeutics (CGTX), ALX Oncology (ALXO), and Cara Therapeutics (CARA). These companies are all part of the "pharmaceutical products" industry. Sunshine Biopharma vs. Its Competitors Enlivex Therapeutics SCYNEXIS Dyadic International Coeptis Therapeutics Tempest Therapeutics NeuroSense Therapeutics Cadrenal Therapeutics Cognition Therapeutics ALX Oncology Cara Therapeutics Sunshine Biopharma (NASDAQ:SBFM) and Enlivex Therapeutics (NASDAQ:ENLV) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, risk, media sentiment, analyst recommendations and institutional ownership. Do insiders & institutionals have more ownership in SBFM or ENLV? 42.0% of Sunshine Biopharma shares are owned by institutional investors. Comparatively, 1.0% of Enlivex Therapeutics shares are owned by institutional investors. 0.1% of Sunshine Biopharma shares are owned by company insiders. Comparatively, 12.3% of Enlivex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Do analysts recommend SBFM or ENLV? Sunshine Biopharma currently has a consensus price target of $15.00, indicating a potential upside of 903.34%. Enlivex Therapeutics has a consensus price target of $10.00, indicating a potential upside of 713.01%. Given Sunshine Biopharma's higher probable upside, research analysts clearly believe Sunshine Biopharma is more favorable than Enlivex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sunshine Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Enlivex Therapeutics 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 3.33 Which has preferable earnings and valuation, SBFM or ENLV? Sunshine Biopharma has higher revenue and earnings than Enlivex Therapeutics. Enlivex Therapeutics is trading at a lower price-to-earnings ratio than Sunshine Biopharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSunshine Biopharma$34.87M0.20-$5.13M-$150.88-0.01Enlivex TherapeuticsN/AN/A-$15.01M-$0.66-1.86 Does the media refer more to SBFM or ENLV? In the previous week, Sunshine Biopharma and Sunshine Biopharma both had 1 articles in the media. Sunshine Biopharma's average media sentiment score of 1.92 beat Enlivex Therapeutics' score of 1.87 indicating that Sunshine Biopharma is being referred to more favorably in the media. Company Overall Sentiment Sunshine Biopharma Very Positive Enlivex Therapeutics Very Positive Is SBFM or ENLV more profitable? Enlivex Therapeutics has a net margin of 0.00% compared to Sunshine Biopharma's net margin of -13.88%. Sunshine Biopharma's return on equity of -21.25% beat Enlivex Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sunshine Biopharma-13.88% -21.25% -16.89% Enlivex Therapeutics N/A -57.67%-50.52% Which has more risk and volatility, SBFM or ENLV? Sunshine Biopharma has a beta of 1.44, meaning that its share price is 44% more volatile than the S&P 500. Comparatively, Enlivex Therapeutics has a beta of 0.79, meaning that its share price is 21% less volatile than the S&P 500. SummarySunshine Biopharma beats Enlivex Therapeutics on 9 of the 15 factors compared between the two stocks. Get Sunshine Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for SBFM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SBFM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SBFM vs. The Competition Export to ExcelMetricSunshine BiopharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.82M$2.92B$5.56B$9.28BDividend YieldN/A2.43%4.23%4.03%P/E Ratio-0.0120.3128.6419.62Price / Sales0.20299.14430.8295.68Price / CashN/A43.1536.0257.93Price / Book0.167.658.155.59Net Income-$5.13M-$55.11M$3.24B$257.73M7 Day Performance-4.17%-0.23%-0.64%-0.23%1 Month Performance-7.14%7.20%4.92%7.98%1 Year Performance348.95%-3.60%25.99%13.16% Sunshine Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SBFMSunshine Biopharma3.3722 of 5 stars$1.50-0.9%$15.00+903.3%+346.2%$6.82M$34.87M-0.013Positive NewsENLVEnlivex Therapeutics2.8436 of 5 stars$1.21+2.5%$10.00+726.4%-12.8%$27.91MN/A-1.8370SCYXSCYNEXIS1.0539 of 5 stars$0.71-3.2%N/A-65.1%$27.62M$2.63M-1.2660Positive NewsDYAIDyadic International3.1294 of 5 stars$0.92-2.6%$6.00+555.4%-31.0%$27.55M$3.34M-4.587Positive NewsGap UpCOEPCoeptis Therapeutics0.5043 of 5 stars$7.73+2.5%N/A+62.4%$26.49M$62.87K-1.332News CoverageGap DownTPSTTempest Therapeutics2.3472 of 5 stars$7.08-0.7%$30.00+323.7%-76.8%$26.26MN/A-0.3920Positive NewsNRSNNeuroSense Therapeutics2.4624 of 5 stars$2.09+9.4%$14.00+569.9%+114.3%$26.10MN/A-3.8710Gap UpCVKDCadrenal Therapeutics2.9296 of 5 stars$12.95-0.2%$32.00+147.1%N/A$25.53MN/A-1.404CGTXCognition Therapeutics2.9169 of 5 stars$0.58+42.9%$2.83+389.5%-70.4%$25.11MN/A-0.7820News CoverageGap UpHigh Trading VolumeALXOALX Oncology3.54 of 5 stars$0.44-3.5%$3.30+643.2%-94.2%$24.57MN/A-0.1840CARACara Therapeutics0.2157 of 5 starsN/AN/AN/A$24.33M$7.14M-0.2580Gap DownHigh Trading Volume Related Companies and Tools Related Companies ENLV Competitors SCYX Competitors DYAI Competitors COEP Competitors TPST Competitors NRSN Competitors CVKD Competitors CGTX Competitors ALXO Competitors CARA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SBFM) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | SponsoredIs this secretive Asian company trying to take over Bitcoin?A mysterious Asian conglomerate is buying billions in Bitcoin — but one legendary trader says that’s the wrong...Brownstone Research | SponsoredBank of America Says Gold Could Hit $4,000. Here How to Get Paid“I’ve always hated gold. It doesn’t pay dividends… it just sits there.” That’s what one income strategist b...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sunshine Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sunshine Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SBFM Stock Alerts